Cargando…

Progressive Pulmonary Fibrosis After Non-Critical COVID-19: A Case Report

Patient: Male, 42-year-old Final Diagnosis: Pulmonary fibrosis Symptoms: Dyspnea Medication:— Clinical Procedure: — Specialty: General and Internal Medicine • Pulmonology OBJECTIVE: Unusual clinical course BACKGROUND: The COVID-19 global pandemic is ongoing, and despite vaccination efforts, SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doane, Jedediah J., Hirsch, Kellen S., Baldwin, Justine O., Wurfel, Mark M., Pipavath, Sudhakar N., West, T. Eoin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650386/ https://www.ncbi.nlm.nih.gov/pubmed/34848676 http://dx.doi.org/10.12659/AJCR.933458

Ejemplares similares

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
por: Bhatraju, Pavan K., et al.
Publicado: (2020)

Comparison of Clinical Features and Outcomes in Critically Ill Patients Hospitalized with COVID-19 versus Influenza
por: Cobb, Natalie L., et al.
Publicado: (2021)

MicroRNAs as potential targets for progressive pulmonary fibrosis
por: Rajasekaran, Subbiah, et al.
Publicado: (2015)

Imaging of Lung Transplantation
por: Ahuja, Jitesh, et al.
Publicado: (2018)

Plasma Soluble CD14 Subtype Levels Are Associated With Clinical Outcomes in Critically Ill Subjects With Coronavirus Disease 2019
por: Mabrey, F. Linzee, et al.
Publicado: (2021)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis
por: Kraemer, Richard, et al.
Publicado: (2006)

Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework
por: Langford, Bryony, et al.
Publicado: (2021)

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis
por: Takei, Reoto, et al.
Publicado: (2023)

Dyspnoea with progressive “idiopathic” pulmonary fibrosis
por: Puri, Chahat, et al.
Publicado: (2021)

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis
por: Platenburg, Mark G. J. P., et al.
Publicado: (2023)

Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study
por: Bhatraju, Pavan K., et al.
Publicado: (2021)

Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis
por: Wang, Xiao Mei, et al.
Publicado: (2006)

Radiographic Findings and Association With Clinical Severity and Outcomes in Critically Ill Patients With COVID-19
por: Wu, Wei, et al.
Publicado: (2022)

Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis
por: Wallis, Tim JM, et al.
Publicado: (2022)

Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5
por: Currie, Simon L., et al.
Publicado: (2017)

Holistic management of patients with progressive pulmonary fibrosis
por: Oliveira, Ana, et al.
Publicado: (2023)

Academic careers in global pulmonary and critical care medicine
por: Papali, Alfred, et al.
Publicado: (2020)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
por: Nashatyreva, Maria S., et al.
Publicado: (2023)

Delineating associations of progressive pleuroparenchymal fibroelastosis in patients with pulmonary fibrosis
por: Gudmundsson, Eyjolfur, et al.
Publicado: (2023)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Multi-Omic Biomarkers Improve Indeterminate Pulmonary Nodule Malignancy Risk Assessment
por: Lastwika, Kristin J., et al.
Publicado: (2023)

Progressive Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
por: Rose, Jonathan A., et al.
Publicado: (2022)

Pulmonary Fibrosis—Tuberculous and Non-Tuberculous
por: Lyall, W. Leslie
Publicado: (1925)

Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis
por: Balestro, Elisabetta, et al.
Publicado: (2016)

Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
por: Kärkkäinen, Miia, et al.
Publicado: (2019)

Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis
por: Kou, Leiya, et al.
Publicado: (2022)

ASK1ng to Delay the Progression of Pulmonary Fibrosis
por: Schuliga, Michael, et al.
Publicado: (2022)

Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse
por: Johannson, Kerri A., et al.
Publicado: (2022)

Progressive pulmonary fibrosis: an expert group consensus statement
por: Rajan, Sujeet K., et al.
Publicado: (2023)

Exploring the Mechanism Whereby Sinensetin Delays the Progression of Pulmonary Fibrosis Based on Network Pharmacology and Pulmonary Fibrosis Models
por: Xu, Yong, et al.
Publicado: (2021)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections
por: Durfey, Samantha L., et al.
Publicado: (2021)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Critical appraisal of the quality of clinical practice guidelines for idiopathic pulmonary fibrosis
por: Li, Xuanlin, et al.
Publicado: (2020)

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2019)

The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis
por: Hanaka, Tetsuya, et al.
Publicado: (2019)

Aberrant Multiciliogenesis in Pulmonary Fibrosis: Bystander or Driver of Disease Progression?
por: Ghanem, Mada, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_emjcfnivkpaaq0t0srl677n2de